Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) Southwest Oncology Group |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00077428 |
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with doxorubicin may kill more tumor cells.
PURPOSE: This phase II trial is studying how well bortezomib followed by doxorubicin at the time of disease progression works in treating patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (cancer) of the head and neck.
Condition | Intervention | Phase |
---|---|---|
Head and Neck Cancer |
Drug: bortezomib Drug: doxorubicin hydrochloride |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck |
Study Start Date: | June 2004 |
Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 8 years.
PROJECTED ACCRUAL: A total of 23-37 patients will be accrued for this study within 2.3 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed adenoid cystic carcinoma of the head and neck
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
No prior anthracyclines, including any of the following:
Endocrine therapy
Radiotherapy
Surgery
Other
United States, Florida | |
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida | |
Tampa, Florida, United States, 33612-9497 | |
United States, New Hampshire | |
Norris Cotton Cancer Center at Dartmouth - Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756-0002 | |
United States, Pennsylvania | |
Hillman Cancer Center at University of Pittsburgh Cancer Institute | |
Pittsburgh, Pennsylvania, United States, 15232 | |
Lewistown Hospital | |
Lewistown, Pennsylvania, United States, 17044 | |
Mount Nittany Medical Center | |
State College, Pennsylvania, United States, 16803 | |
Penn State Cancer Institute at Milton S. Hershey Medical Center | |
Hershey, Pennsylvania, United States, 17033-0850 | |
United States, Wisconsin | |
Froedtert Hospital and Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 | |
Medical College of Wisconsin Cancer Center | |
Milwaukee, Wisconsin, United States, 53226 |
Study Chair: | Athanassios Argiris, MD | UPMC Cancer Centers |
Investigator: | Barbara A. Burtness, MD | Yale University |
Investigator: | Madeleine A. Kane, MD, PhD | University of Colorado at Denver and Health Sciences Center |
Study ID Numbers: | CDR0000350319, ECOG-E1303, SWOG-ECOG-E1303 |
Study First Received: | February 10, 2004 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00077428 History of Changes |
Health Authority: | United States: Food and Drug Administration |
recurrent adenoid cystic carcinoma of the oral cavity stage III adenoid cystic carcinoma of the oral cavity stage IV adenoid cystic carcinoma of the oral cavity recurrent salivary gland cancer |
stage III salivary gland cancer stage IV salivary gland cancer salivary gland adenoid cystic carcinoma |
Bortezomib Disease Progression Recurrence Doxorubicin Carcinoma Protease Inhibitors Anti-Bacterial Agents |
Carcinoma, Adenoid Cystic Head and Neck Neoplasms Adenoid Cystic Carcinoma Adenocarcinoma Salivary Gland Diseases Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Bortezomib Enzyme Inhibitors Antibiotics, Antineoplastic Pharmacologic Actions Doxorubicin Protease Inhibitors |
Carcinoma Neoplasms Neoplasms by Site Carcinoma, Adenoid Cystic Head and Neck Neoplasms Therapeutic Uses Adenocarcinoma Neoplasms, Glandular and Epithelial |